LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting

LF111 vs. Non-hormonalLF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Sponsor:

Insud Pharma

Code:

NCT05303636

Conditions

Change in Bone Mineral Density

Bone Loss

Eligibility Criteria

Sex: Female

Age: 14 - 45

Healthy Volunteers: Accepted

Interventions

LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Insud Pharma on 2023-06-18.